Table 6.
Agents | Objects | Gender | Weight (g) | Animal model | Dose | Time periods | Mechanisms | References |
---|---|---|---|---|---|---|---|---|
Asiatic acid | C57BL/6 | male | 22–27 | pMCAO | 30, 75, and 165 mg/kg, i.g. | 1 h before and 3, 10, and 20 h after pMCAO | Cyto-c↓, BBB permeability (IgG)↓ | Krishnamurthy et al., 2009 |
Ginsenoside Rd | SD | male | 270–320 | MCAO | 50 mg/kg, i.p. | 30 min before MCAO | MMP↑, aconitase↑, mitochondrial complexes I-IV↑; ROS↓, lactate/pyruvate ratio↓, cleaved Caspase-3, Cyto-c↓, AIF↓ | Ye et al., 2011b |
Genistein | C57/BL6J | male | 24–28 | MCAO (1 h)/R (24 h) | 2.5, 5, and 10 mg/kg, i.g. | Pretreatment once daily for 2 w | SOD↑, GSH-Px↑, mitochondrial Cyto-c↑; MDA↓, mtROS↓, cytosolic Cyto-c↓, Caspase-3↓, TUNEL-positive neurons↓, p-NF-κB p65 subunit↓, p-IκBα↓ | Qian et al., 2012 |
Oxysophoridine | ICR | male | 20–25 | MCAO (2 h)/R (24 h) | 62.5, 125, and 250 mg/kg, i.p. | Pretreatment once daily for 1 w | SOD↑, GSH-Px↑, Bcl-2↑; MDA↓, Caspase-3↓, Bax↓, TUNEL-positive neurons↓ | Wang et al., 2013 |
Echinacoside | SD | both | 12–17 | Permanent ligation of the left CCA plus low oxygen atmosphere (8% O2, 92% N2) for 2.5 h | 40, 80, and 160 mg/kg, i.p. | Every 12 h after operation, a total of 4 times | SOD↑, GSH-Px↑, CAT↑, T-AOC↑, Bcl-2/Bax↑; MDA↓, Caspase-3↓, TUNEL-positive neurons↓ | Wei W. et al., 2019 |
Gallic acid | SD | male | 250–300 | MCAO (2 h)/R (24 h) | 25 and 50 mg/kg, i.v. | 20 min before MCAO | MMP↑, mitochondrial Cyto-c↑; MDA↓, ROS↓, cytosolic Cyto-c↓, TUNEL-positive neurons↓ | Sun et al., 2014 |
SD | male | 250–300 | MCAO | 50 mg/kg | binding capacity of CypD and ANT-1↓, MPTP openinng↓, p-ERK↓, Cyto-c↓, cleaved Caspase-3/8/9↓ | Sun et al., 2017 | ||
Oxymatrine | SD | both | —— | Permanent ligation of the left CCA plus low oxygen atmosphere (8% O2, 92% N2) for 2.5 h | 30, 60, and 120 mg/kg, i.p. | Every 12 h after operation, a total of 2 times | SOD↑, GSH-Px↑, CAT↑, T-AOC↑, Bcl-2/Bax↑, MDA↓, Caspase-3↓, neuronal apoptosis under flow cytometry↓ | Zhao et al., 2015a |
Matrine | ICR | male | 20–25 | MCAO (2 h)/R (24 h) | 7.5, 15, and 30 mg/kg, i.p. | Pretreatment once daily for 1 w | SOD↑, GSH-Px↑, CAT↑, T-AOC↑, Bcl-2/Bax↑, MDA↓, Caspase-3↓, neuronal apoptosis under flow cytometry↓ | Zhao et al., 2015b |
Taurine | SD | both | —— | Permanent ligation of the left CCA plus low oxygen atmosphere (8% O2, 92% N2) for 2 h | 30, 60, and 120 mg/kg, i.p. | Every 12 h after operation, a total of 2 times | SOD↑, GSH-Px↑, T-AOC↑, Bcl-2/Bax↑, ATP↑; LA↓; MPO↓, MDA↓, AIF↓, Cyto-c↓ | Zhu et al., 2016 |
HSYA | Wistar | male | 220–250 | MCAO (1 h)/R (24 h) | 8 mg/kg, i.v. | After reperfusion | GSH↑, CAT↑; MDA↓, TNF-α↓, MPTP opening↓ | Ramagiri and Taliyan, 2016 |
Curcumin | Wistar | male | 180–200 | MCAO/R | 25 mg/kg, i.p. | Bcl-↑, Sirt1↑, MMP ↑; p53↓, Bax↓, IL-6↓, TNF-α↓, ROS↓ | Zhang et al., 2017 | |
Picroside II | Wistar | male | 240–260 | MCAO (2 h)/R (24 h) | 20 mg/kg, i.p. | 15 min before MCAO/R. | VDAC1↓, cytoplasmic and nuclear EndoG↓, ROS↓, MPTP opening↓, TUNEL-positive neurons↓ | Li S. et al., 2018 |
Rhein | SD | male | 260–300 | MCAO (2 h)/R (72 h) | 25, 50, and 100 mg/kg, i.g. | 3 days following MCAO/R | SOD↑, GSH-Px↑, CAT↑, Bcl-2/Bax ratio↑; MDA↓, Caspase-3/9↓, cleaved Caspase-3↓ | Zhao et al., 2018b |
Genipin | C57BL/6 | male | 25–30 | MCAO (1 h)/R (24 h) | 50 mg/kg, i.g. | Pretreatment once daily for 3 d | ATP↑, SOD↑, GSH↑; UCP2↓, SIRT3↓, NAD+/NADH↓, LDH↓, cleaved Caspase-3↓, TUNEL-positive neurons↓ | Zhao B. et al., 2019 |
Swertiamain | ICR | male | 20–25 | MCAO (2 h)/R (24 h) | 25, 100, and 400 mg/kg, i.p. | Pretreatment once daily for 1 w | Bcl-2/Bax↑, SOD↑, GSH-Px↑, CAT↑, GSH↑, nulcear Nrf2↑, HO-1↑, NQO1↑; MDA↓, Keap1↓, cytoplasmic Nrf2↓, TUNEL-positive neurons↓ | Wang et al., 2019b |
↑, upgrade; ↓, downgrade.